|
Paroxysmal nocturnal hemoglobinuria: Where are we going |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
May 2023 |
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
|
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
Jun 2023 |
Haematologica |
Aplastic Anemia |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study |
Jun 2023 |
European Journal of Haematology |
Aplastic Anemia |
|
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
Jun 2023 |
Molecular Medicine |
Aplastic Anemia |
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Jun 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
